← Back to Clinical Trials
Recruiting NCT05372484

NCT05372484 Rice Technologies for Cervical Cancer Screening and Diagnosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05372484
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Cervical Cancer
Study Type INTERVENTIONAL
Enrollment 678 participants
Start Date 2021-03-24
Primary Completion 2028-03-30

Eligibility & Interventions

Sex Female only
Min Age 25 Years
Max Age 49 Years
Study Type INTERVENTIONAL
Interventions
Multimodal optical imaging

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 678 participants in total. It began in 2021-03-24 with a primary completion date of 2028-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

Eligibility Criteria

Inclusion Criteria: 1. 25 - 49 year old women 2. Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test) 3. Women with intact cervix 4. Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding 5. Willing and capable of providing informed consent Exclusion Criteria: 1. Women under 25 or over 49 years old 2. Women who have undergone a total hysterectomy (with removal of the cervix) 3. Women who are pregnant or breastfeeding

Contact & Investigator

Central Contact

Mila Salcedo, MD, PhD

✉ mpsalcedo@mdanderson.org

📞 (832) 696-6794

Principal Investigator

Kathleen Schmeler, MD

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT05372484 clinical trial?

This trial is open to female participants only, aged 25 Years or older, up to 49 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05372484 currently recruiting?

Yes, NCT05372484 is actively recruiting participants. Contact the research team at mpsalcedo@mdanderson.org for enrollment information.

Where is the NCT05372484 trial being conducted?

This trial is being conducted at Houston, United States, Maputo, Mozambique, Maputo, Mozambique, Maputo, Mozambique.

Who is sponsoring the NCT05372484 clinical trial?

NCT05372484 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Kathleen Schmeler, MD at M.D. Anderson Cancer Center. The trial plans to enroll 678 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology